The stock price performance over the year has been a mixed bag, resulting in a range of outlooks from optimistic to pessimistic depending on the observer. This year’s metric has recorded a Price increase of 21.95%. However, over the past six months, we’ve seen a weaker performance of 44.70%. The price of CRSP fallen by 8.72% over the last 30 days. And in the last five days, it has surged by 1.76%.
The stock price for CRISPR Therapeutics AG (CRSP) currently stands at $57.33. The stock experienced a substantial increase in the last session, hitting $268.0 after starting at $57.33. The stock’s lowest price was $32.0 before closing at $56.6.
CRISPR Therapeutics AG experienced a somewhat steady performance in the stock market. The company’s stock reached a 1-year high of $71.13 on 07/21/25, while the lowest price for the same period was registered at $30.04 on 04/07/25.
52-week price history of CRSP Stock
Examining the 52-week high and low prices can provide valuable insights into a stock’s current status and future performance. CRISPR Therapeutics AG’s current trading price is -19.40% away from its 52-week high, while its distance from the 52-week low is 90.85%. The stock’s price range during this time has been between $30.04 and $71.13. The trading volume for the Healthcare sector company’s shares reached about 6.92 million for the day, which was higher than the average daily volume of 3.14 million over the last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
CRISPR Therapeutics AG (CRSP) has experienced a quarterly rise of 54.03% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 5.21B and boasts a workforce of 393 employees.
CRISPR Therapeutics AG: Analysts’ Ratings Unveiled
As of right now, 11 analysts are rating CRISPR Therapeutics AG as a BUY, 5 of the polled analysts branded the stock as an OVERWEIGHT, 10 analysts are recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 1 analyst is rating the stock as SELL.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 44.66, with a change in price of +16.16. Similarly, CRISPR Therapeutics AG recorded 2,849,585 in trading volume during the last 100 days, posting a change of +39.25%.
CRSP’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for CRSP stands at 0.13. Similarly, the long-term debt-to-equity ratio is also 0.12.
CRSP Stock Stochastic Average
Today’s raw stochastic average for CRISPR Therapeutics AG over the last 50 days is 60.63%.This indicates a increase from the raw stochastic average of the past 20 days, which was 25.93%. Moreover, the company’s Stochastic %K and %D values for the last 20 days were 21.44% and 18.53%, respectively.
